Understandably, the recent FDA warning against homeopathic teething tablets and FTC policy statement on homeopathic labeling requirements have concerned many providers and patients alike. OANP is carefully monitoring these activities in conjunction with the American Association of Naturopathic Physicians, which has testified numerous times before government agencies in support of homeopathics (thanks to Dr. Paul Herscu!).
We wanted to share recent information from the National Center for Homeopathy (NCH) and the American Association of Homeopathic Pharmacists (AAHP). Along with the AANP, these two organizations have been spearheading efforts to negotiate with and provide testimony to government agencies.
At this time, they advise the homeopathic community to stay positive and refrain from attacking federal agencies. There is a lot of behind the scenes discussions happening, and there is no need for community members to contact the FDA or FTC directly, as it might be harmful to ongoing negotiations.
It’s important to understand that the FDA and FTC have been scrutinizing homeopathy for the past two years, so this is not something new or unexpected. As regulatory agencies, they both have the right to do so, with their jurisdiction covering different things.
The FTC statement is specifically around advertising for homeopathic medicines sold over the counter (OTC). They are requiring scientific proof of effectiveness for advertising purposes, and their ruling effects all OTC homeopathics, not just combination remedies.
Prescription products fall under the jurisdiction of the FDA, which does not require proof of effectiveness through clinical research. These issues are complex, and require a deep understanding of the government mechanism behind it.